Next week BioIVT will attend the Association
for Diagnostics & Laboratory Medicine (ADLM) annual meeting and
the Alzheimer's Association International Conference (AAIC)
WESTBURY, N.Y., July 25,
2024 /PRNewswire/ -- BioIVT, a global research
partner and biospecimen solutions provider for drug and diagnostic
development, today announced it will attend two leading industry
conferences focused on research and developments for both general
and neurodegenerative disease diagnostics and treatments. From
July 28 - August 1, one group of
BioIVT's experts will attend ADLM 2024 in Chicago, and another team will simultaneously
attend AAIC 2024 in Philadelphia.
BioIVT will have a booth at each event where the company will
detail how BioIVT fuels innovative research for a comprehensive
range of diseases. At ADLM, BioIVT will focus on support for
diagnostic lab medicine, including clinically collected
biospecimens across a broad range of disease indications, normal
human and animal biofluids such as whole blood plasma and serum
from any commercially available animal strain, as well as donor
center quality control matrices from its KEYSTONE facility.
At AAIC, BioIVT will focus on support for Alzheimer's,
Parkinson's, Amyotrophic Lateral Sclerosis (ALS) and Multiple
Sclerosis (MS), by providing high-quality biospecimens and research
services to the life science industry. Launched in 2023, BioIVT's
Center for NeuroExcellence gives researchers across the world
near-immediate access to neuro-related disease samples to help
facilitate breakthroughs in genetics, drug discovery, biomarker
research, and molecular diagnostics. The company is the largest
private global source of longitudinally collected human
cerebrospinal fluid from living normal control as well as diseased
populations.
"BioIVT's extensive portfolio of high-quality and readily
available clinical samples can be collected to meet specific
research needs for all disciplines, including neuroscience," said
Courtney Noah, Ph.D., Vice President
of Scientific Affairs at BioIVT. "At ADLM and AAIC, we look forward
to convening with and learning from some of the top minds in the
diagnostic lab medicine and neuroscience research communities, and
sharing more about our solutions that are elevating science and
driving drug and diagnostic development."
With a global network comprised of 11 donor centers and 425
clinical sites, BioIVT is the worldwide leader of biological
products to pharmaceutical, biotechnology, and academic
researchers. The company is committed to providing the highest
quality human and animal biological matrices and processing
services, as well as excellent customer support.
You can find the BioIVT team at booth #1005 at ADLM and booth
#922A at AAIC.
About BioIVT
BioIVT enables smarter science and accelerates medical
breakthroughs by delivering high-quality personalized biospecimen
solutions and research services to the life science and diagnostic
industries. We specialize in control and disease state samples
including human and animal tissues or preparations, ADME-Tox
products and research services, cell and gene therapy products,
blood, and other biofluids. Our unmatched portfolio of clinical
specimens directly supports precision medicine research and the
effort to improve patient outcomes by coupling comprehensive
clinical data with donor samples. By combining our technical
expertise, exceptional customer service, and unparalleled access to
biological specimens, BioIVT serves the research community as a
trusted partner in ELEVATING SCIENCE®. For more
information, please visit bioivt.com or follow us on
LinkedIn.
BioIVT Contact: Charlie Chungu, Vice President of
Marketing, cchungu@bioivt.com
Media Contact: Alex
Connelly, PAN, 401-486-7437, BioIVT@pancomm.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bioivt-to-highlight-its-integral-role-in-drug-and-diagnostic-discovery-and-development-in-addition-to-neuroscience-research-at-premier-life-science-events-302205765.html
SOURCE BioIVT